Product Information
RYTARY ER 61.25 MG-245 MG CAP is a brand product labeled by Amneal Pharmaceuticals LLC, priced at $4.9972 per EA under NDC 64896066401. Its NADAC has been published 555 times since Feb 17, 2016.
FDA first approved this application on Jan 7, 2015.
The High Outlier badge above means this manufacturer's average price in the Carbidopa and Levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
61.25; 245 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals LLCNDC
64896066401
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA HYDRATE; LEVODOPAApproval Type
New Drug (NDA)
FDA Application
NDA203312FDA Approved
1/7/2015
On Market Since
1/12/2015
Pharmacological Classes
Price Statistics
The NADAC for RYTARY ER 61.25 MG-245 MG CAP has been published 555 times since Feb 17, 2016, and over the history we have for it it has risen 79.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.9972 per EA |
|---|---|
| All-time high | $5.0118 (Apr 16, 2025) |
| All-time low | $2.7924 (Feb 17, 2016) |
| 52-week high | $4.9996 |
| 52-week low | $4.9916 |
| Median price | $4.2009 |
| Average price | $4.1727 |
| Largest weekly change | +9.9% (Feb 9, 2022) |
| Weeks tracked | 555 |
| Tracking since | Feb 17, 2016 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 30% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and Levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RYTARY ER 61.25 MG-245 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for RYTARY ER 61.25 MG-245 MG CAP, manufactured by Amneal Pharmaceuticals LLC, is $4.9972 per EA (NDC 64896066401), effective Sep 30, 2026.
How has the price of RYTARY ER 61.25 MG-245 MG CAP changed over time?
Over the history we have for it, the NADAC for RYTARY ER 61.25 MG-245 MG CAP has risen 79.0%. It has been tracked across 555 weekly CMS publications since Feb 17, 2016.
What are the highest and lowest recorded NADAC prices for RYTARY ER 61.25 MG-245 MG CAP?
Since Feb 17, 2016, the NADAC for RYTARY ER 61.25 MG-245 MG CAP has ranged from a low of $2.7924 (Feb 17, 2016) to a high of $5.0118 (Apr 16, 2025), with a median of $4.2009 per EA.
Are there cheaper alternatives to RYTARY ER 61.25 MG-245 MG CAP?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RYTARY ER 61.25 MG-245 MG CAP, is $3.5009 per EA — about 30% below RYTARY ER 61.25 MG-245 MG CAP.
Who manufactures RYTARY ER 61.25 MG-245 MG CAP?
RYTARY ER 61.25 MG-245 MG CAP (NDC 64896066401) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a brand product.